|
Interview
Who has costs is afraid!
The present Institutional Relations Director at Cristália, majored in Business Administration from Escola Superior de Administração e Negócios, Odilon Costa, fully understands the pharmaceutical chain in its whole. During an exclusive interview to Top Team he talks about trends, competitiveness and Public-Private Partnership.
"Nowadays the local production of active pharmaceutical ingredient (API) is highly valued. Thus, there is room for national reindustrialization and the creation of new companies dedicated to Biotechnology", points out the executive, who has already worked at UCI-Farma, Enila and Synthelabo.
With specialization in Marketing from Fundação Getúlio Vargas, the Institutional Relations Director at Cristália adds that in order to be more competitive "we need to quickly and efficiently solve the so-called "Brazilian Cost".
Follow up the main parts of the interview:
Top Team: Is healthcare one of the priorities of the federal government?
Odilon Costa: Absolutely. Healthcare is top ranked in the government agenda. It is just a matter of observing the speeches of the Brazilian President and the events around the Health Industrial Complex. Thus, Brazil realized that its internal market is a national heritage and that is able to support the growth of those who are here and invest in productive capital.
Top Team: Are the executives of the pharmaceutical market able to see the scenario concerning health?
Odilon Costa: We, executives of the pharmaceutical industry, seem to have myopia, as we just see the market and forget to include health in the public healthcare. Nowadays, the government works much better than yesterday the purchasing power of the state and then it becomes the Public-Private partnership.
Top Team: Nowadays, in the pharmaceutical chain, what is the major discussion?
Odilon Costa: That´s reindustrialization. The local production of active pharmaceutical ingredient (API) is highly valued. Thus, there is room for national reindustrialization and the creation of new companies dedicated to Biotechnology.
Top Team: What does the Brazilian pharmaceutical industry need to do in order to be more competitive?
Odilon Costa: In order to be more competitive we need to quickly and efficiently solve the so-called "Brazilian Cost", that´s why I have said that "Who has costs is afraid!". They include everything in our costs and we can´t include ours in nobody´s costs. That´s impossible, therefore, to be more competitive with higher prices, pressed by the "Brazilian Cost" and high interests stealing the productive capital and feeding the speculative capital.
Top Team: To wrap up, within this context, what other measures can be taken in Brazil?
Odilon Costa: We also need to increase the technology access and innovation. Also, we need to have politicians willing to adjust the industrial policy to minimize uncertainty and intensify a national mobilization of those who are able to make a Greater Brazil.
|
Print this page
Mail this page